Evidence map›Paper›PMID 40681266›Full record

ArticleJACC. Case reports2025

Pulmonary Arterial Hypertension After Busulfan Administration During Conditioning Regimen in Neuroblastoma: Key Role of Rescue Treatment.

Rachele Adorisio, Gessica Ingrasciotta, Francesco Fabozzi, Aurelio Secinaro, Paolo Tomà, Federica Cavallo, Angela Mastronuzzi, Antonio Amodeo, Franco Locatelli, Maria Antonietta De Ioris

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rachele AdorisioAdvanced Cardiovascular Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Electronic address: rachele.adorisio@opbg.net.
Gessica IngrasciottaHeart Failure, Transplant and Mechanical Circulatory Support Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Francesco FabozziHematology/Oncology, Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Aurelio SecinaroThoracic and Advanced Cardiovascular Imaging Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paolo TomàRadiology and Bioimaging Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Federica CavalloHematology/Oncology, Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Angela MastronuzziHematology/Oncology, Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Antonio AmodeoHeart Failure, Transplant and Mechanical Circulatory Support Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
Franco LocatelliHematology/Oncology, Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
Maria Antonietta De IorisHematology/Oncology, Cell and Gene Therapy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary arterial hypertension (PH) is a rare and life-threatening complication of high-dose chemotherapy with busulfan (Bu) used for hematopoietic stem cell transplantation. CASE SUMMARY: A 5-year-old male patient with retroperitoneal neuroblastoma developed PH and acute right-sided heart failure 2 months after conditioning regimen that included Bu and melphalan before autologous hematopoietic stem cell transplantation. Once pulmonary embolism and veno-occlusive disease were excluded by computed tomography, rescue treatment, including epoprostenol, bosentan, and sildenafil, was started, with complete regression of acute right-sided heart failure and normalization of pulmonary pressure. DISCUSSION: Bu can cause PH through different pathophysiological mechanisms. The prompt start of rescue treatment is a cornerstone for a good outcome. In our patient, considering the absence of signs of pulmonary veno-occlusive disease on computed tomography, a triple pulmonary vasodilator therapy was started and a rapid recovery was noted. TAKE-HOME MESSAGE: Early work-up for PH in children after Bu administration is essential to recognize a life-threatening condition requiring a rescue treatment.

Indexed as

busulfanneuroblastomapulmonary hypertension

Identifiers

PMID40681266
PMCPMC12441408

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.